As research continues to better differentiate between eczema and other diagnoses, the National Eczema Association continues to push awareness among patients and physicians with Eczema Awareness Month.
As research continues to better differentiate between eczema and other diagnoses, the National Eczema Association continues to push awareness among patients and physicians with Eczema Awareness Month.
Patients often describe seeking alternatives and adjuncts to care for the treatment of their atopic dermatitis. The literature has explored some of the potential in these options.
Patients often describe seeking alternatives and adjuncts to care for the treatment of their atopic dermatitis. The literature has explored some of the potential in these options.
Phototherapy continues to be a mainstay of psoriasis treatment. Dr Gelfand highlights recommendations for phototherapy administration and patient discussions during the COVID-19 pandemic.
Phototherapy continues to be a mainstay of psoriasis treatment. Dr Gelfand highlights recommendations for phototherapy administration and patient discussions during the COVID-19 pandemic.
The time away from clinic due to the pandemic has left many with time to contemplate current affairs and their dermatology practice. Sarah Patton, MSHS, PA-C, reflects on how her life and career has changed over the course of 4 months.
The time away from clinic due to the pandemic has left many with time to contemplate current affairs and their dermatology practice. Sarah Patton, MSHS, PA-C, reflects on how her life and career has changed over the course of 4 months.
While much of research is to test the clinical efficacy and safety of drugs, these posters from the American Academy of Dermatology Virtual Meeting Experience 2020 focused on physician decision-making and evaluation, patient characteristics,...
While much of research is to test the clinical efficacy and safety of drugs, these posters from the American Academy of Dermatology Virtual Meeting Experience 2020 focused on physician decision-making and evaluation, patient characteristics,...
Kristian Reich, MD, PhD, discussed a therapeutic breakthrough with bimekizumab, a novel biologic in development that inhibits IL-17F in addition to IL-17A.
Kristian Reich, MD, PhD, discussed a therapeutic breakthrough with bimekizumab, a novel biologic in development that inhibits IL-17F in addition to IL-17A.
Atopic dermatitis (AD) is a common chronic inflammatory skin condition that affects 6% to 13% of children and up to 10% of adults in the United States.1,2 This condition commonly emerges in childhood, with up to 85%...
Atopic dermatitis (AD) is a common chronic inflammatory skin condition that affects 6% to 13% of children and up to 10% of adults in the United States.1,2 This condition commonly emerges in childhood, with up to 85%...